PaxMed

Executive Summary

PaxMed is a privately held regulatory affairs leader serving the medical device industry. Founded in 2020 and headquartered in New York, the company leverages AI and machine learning to accelerate market access for device innovations. With a focus on small to large manufacturers, PaxMed provides expertise in navigating complex FDA and international regulatory pathways, enabling clients to bring emerging technologies to market rapidly. As a service-based company with no disclosed funding or pipeline products, PaxMed's growth is driven by the expanding medical device sector and increasing regulatory complexity. The company's digital health and AI capabilities position it well to capitalize on the growing demand for efficient regulatory solutions, though its private status limits public financial visibility. Overall, PaxMed represents a niche but essential player in the medtech ecosystem, with potential for steady revenue growth through client engagements.

Upcoming Catalysts (preview)

• Q3 2026New FDA Guidance on AI/ML-Enabled Medical Devices80% success
• Q2 2026Strategic Partnership with a Major MedTech Manufacturer50% success
• Q4 2026Expansion into European Medical Device Regulation (MDR) Consulting70% success